Breckenridge to commercialize eye products from Korean firm in USA

4 July 2017

US generic drugmaker Breckenridge Pharmaceuticals, a subsidiary of Spain’s Esteve, has entered into a multi-product agreement with South Korean firm Sam Chun Dang Pharm (SCD), under which the two companies expect to develop and commercialize at least seven Abbreviated New Drug Applications (ANDAs) in the USA.

Under the terms of the accord, SCD will develop, manufacture and supply the products exclusively for Breckenridge for the US market and Breckenridge will market and distribute the products in its label. This multi-product agreement represents the first foray for both companies having products developed and manufactured in South Korea for the US market.

This agreement contemplates filing ANDAs for at least six ophthalmic products and one otic product, beginning in the first quarter of 2018. The total addressable IMS market value for this portfolio is $2.4 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK